TY  - JOUR
AU  - Walsh, R
AU  - Locarnini, S
Y2  - 2021/02/04
Y1  - 2012/09/01
SN  - 0513-5796
UR  - http://hdl.handle.net/11343/259062
AB  - Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the host's immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB and liver disease.
LA  - English
PB  - YONSEI UNIV COLL MEDICINE
T1  - Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise
DO  - 10.3349/ymj.2012.53.5.875
IS  - Yonsei Medical Journal
VL  - 53
IS  - 5
SP  - 875-885
L1  - /bitstream/handle/11343/259062/PMC3423855.pdf?sequence=1&isAllowed=y
ER  -